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https://doi.org/10.1016/j.celrep.2020.107826SUMMARYRegulatory T cells (Tregs) represent amajor population in the control of immune homeostasis and autoimmu-
nity. Here we show that Fos-like 2 (Fosl2), a TCR-induced AP1 transcription factor, represses Treg develop-
ment and controls autoimmunity. Mice overexpressing Fosl2 (Fosl2tg) indeed show a systemic inflammatory
phenotype, with immune infiltrates in multiple organs. This phenotype is absent in Fosl2tg 3 Rag2/ mice
lacking T and B cells, and Fosl2 induces T cell-intrinsic reduction of Treg development that is responsible
for the inflammatory phenotype. Fosl2tg T cells can transfer inflammation, which is suppressed by the co-de-
livery of Tregs, while Fosl2 deficiency in T cells reduces the severity of autoimmunity in the EAE model. We
find that Fosl2 could affect expression of FoxP3 and other Treg development genes. Our data highlight the
importance of AP1 transcription factors, in particular Fosl2, during T cell development to determine Treg dif-
ferentiation and control autoimmunity.INTRODUCTION
CD4+ T cells can differentiate into various subsets of helper cells,
which enables the adaptation of the immune response to
different pathogens. Regulatory T cells (Tregs), on the other
hand, are a population of T cells that are able to control other im-
mune cell types. Forkhead box protein P3 (FoxP3) was identified
as the key transcription factor for Treg identification and function
(Bennett et al., 2001; Chatila et al., 2000). The main source of
Tregs is the thymus, where CD4 single-positive (SP) thymocytes
acquire a Treg phenotype directly from the developmental stage
(Owen et al., 2019). These thymic-derived Tregs are called natu-
ral Tregs (nTregs) or thymic Tregs (tTregs) and rely mostly on
T cell receptor (TCR) and IL-2 signals. Mature T cells in the pe-
riphery can also be induced to express FoxP3 and to acquire
suppressive capacities when activated in the presence of IL-2
and TGF-b, giving rise to induced Tregs (iTregs), also called pe-
ripheral Tregs (pTregs) (Chen et al., 2003).
Tregs are central in the control of immune response.
Evidences in humans was provided by an IPEX (immune dysre-
gulation, polyendocrinopathy, enteropathy, X-linked syndrome)This is an open access article under the CC BY-Npatient with a loss-of-function mutation in FoxP3, which clearly
demonstrated the requirement for Tregs to maintain immune
tolerance and prevent autoimmunity (Bennett et al., 2001; Brun-
kow et al., 2001). Studies have also suggested that abnormalities
in Treg numbers, frequencies, and suppressive function could be
involved in the pathomechanisms of multiple autoimmune dis-
eases (Grant et al., 2015). On the other hand, Tregs were also
shown to suppress antitumor responses, worsening disease
outcome (Facciabene et al., 2012). Although recent data have
provided good knowledge of the identity and function of Tregs,
how the fate decision and differentiation of these cells are
controlled is still only partly understood.
Fos-like 2 (Fosl2; also called Fos-related antigen-2 [Fra-2]) is a
member of the Fos family and belongs to the AP1 transcription
complex. AP1 is a complex network of heterodimers formed by
proteins of the Jun, Fos, ATF, and MAF families, comprising
more than 20 proteins in total. These AP1 proteins have a basic
DNA-binding domain that is active only when the protein forms a
dimer through its leucine zipper region.With the exception of Jun
proteins that can form homodimers, other AP1 proteins always




OPEN ACCESS(Hess et al., 2004). So far, Fosl2 interactions with Jun, JunB,
JunD, and ATF7 have been confirmed (Mathas et al., 2009; Ma-
zur et al., 2015; Bozec et al., 2013). Of note, these Jun proteins
can themselves interact with other Fos or ATF proteins, creating
a vast network of dimers exerting both redundant and unique
functions (Hess et al., 2004). This mode of action has limited
our understanding of individual AP1 protein functions, and AP1
is often referred to as one transcription complex irrespective of
the proteins involved. So far, Fosl2 has been found to control
bone formation (Bozec et al., 2010), promote fibrosis through
fibroblast activation (Eferl et al., 2008), and participate in the con-
trol of B cell development (Ubieta et al., 2017). However, Fosl2
was initially thought to play a minimal role in T cells, as Fosl2fl/fl
CD4-cre+ mice had no overt T cell phenotype and displayed
only abnormal invariant natural killer T (iNKT) cells (Lawson
et al., 2009). More recently, bioinformatic approaches using mul-
tiple datasets predicted a role for Fosl2 in controlling Th17 plas-
ticity (Ciofani et al., 2012). Interestingly, several genome-wide
association studies (GWASs) also reported associations of sin-
gle-nucleotide polymorphisms (SNPs) within the promoter of
Fosl2 with risk for Crohn’s disease, ulcerative colitis, asthma,
hay fever, and eczema (Jostins et al., 2012; Liu et al., 2015; Ye
and McGovern, 2016; Ferreira et al., 2019), suggesting a
possible role for Fosl2 in the control of inflammatory diseases.
AP1 members are known to contribute to Treg biology.
Several binding sites have been found in the promoter and
enhancer of FoxP3, and Jun and Fos in particular have been sug-
gested to promote FoxP3 expression (Mantel et al., 2006; Bao
et al., 2016). JunB was also identified to promote effector Treg
homeostasis and suppressive function (Koizumi et al., 2018). In
opposition, Batf3 was shown to repress Treg differentiation in
the periphery, highlighting the diverse contributions of AP1 to
Treg biology (Lee et al., 2017). So far the contribution of Fosl2
to AP1 function in T cells and in the control of inflammation
and autoimmunity remains unknown.
RESULTS
Fosl2tg Mice Develop a Multi-organ Inflammatory
Phenotype
To explore the function of Fosl2, we analyzed the effects of both
Fosl2 deficiency and Fosl2 overexpression. We generated a
Fosl2 transgenic mouse strain (Fosl2tg) in which the murine
Fosl2 gene was randomly inserted under the control of the major
histocompatibility complex class I (MHCI) promotor H2Kb (Fig-
ure S1A), using a similar strategy as previously described (Eferl
et al., 2008). To obtain Fosl2-deficient T cells, we used Fosl2fl/fl
and CD4-cre mice (Eferl et al., 2007) (Figure S1B). Successful
deletion and overexpression of Fosl2 were confirmed on
mRNA and protein levels in T cells from Fosl2fl/flCD4-cre+ and
Fosl2tg mice (Figures S1C and S1D).
We observed a spontaneous phenotype in Fosl2tg mice. All
Fosl2tg mice developed dermatitis around the eyes, evidenced
by extensive swelling and fur loss (Figures 1A and S2A). Interest-
ingly, there was a difference in the onset of dermatitis develop-
ment between males and females, with skin lesions developing
at a median age of 13 weeks for females and 17.5 weeks for
males. Dermatitis also affected the back and tail skin in certain2 Cell Reports 31, 107826, June 30, 2020mice but did not involve paws or ears. Histological analysis of
affected skin revealed multifocal ulcerating inflammation with
partial acanthosis and hyperkeratosis/hyperparakeratosis.
Leukocyte infiltrates were present in the subcutaneous layer,
dermis, and epidermis (Figure 1B).
Upon dissection, macroscopic examination of the mice also
showed enlarged thymus, salivary glands, spleen, lungs, liver,
and duodenum. Lungs and thymus were the most commonly
affected organs, whereas other organs were differently affected
between animals. As for skin, females had a more severe organ
phenotype, with higher increases in spleen and liver weight than
in males (Figure S1E).
Histological analysis of these organs revealed that inflamma-
tory infiltrates were present in the lungs, thymus, salivary glands,
pancreas, liver, and duodenum (Figures 1C and 1D; Figure S2B).
In the lungs, there were perivascular and peribronchial leukocyte
infiltrates, as evidenced by CD45 staining. There were also signs
of interstitial pneumonitis with eosinophilic foamy macrophages
and eosinophilic crystals (Figure 1C; Figure S2E). Transgenic
mice displayed hypertrophy of thymus and salivary glands with
inflammation (Figure S2B). Pancreas and liver showed diverse
degrees of inflammation depending on the animals analyzed
(Figure S2B).
Given the inflammation in multiple organs, we decided to
analyze serum cytokines. Levels of 20 cytokines and chemo-
kines were quantified in 12 wild-type (WT) and 12 Fosl2tg mice
at 17 weeks of age by multiplex analysis. Among these cyto-
kines, we observed significant increases in TNF-a and IL-1b,
confirming the strong inflammation present in Fosl2tg mice
(Figure 1E). Interestingly, levels of IL-5 were strongly
increased, which correlated with the eosinophilia observed
in several organs, especially the lungs. There were also
smaller but significant increases in IL-6, IL-9, IL-10, and
CCL-2 (Figure 1E).
Serum levels of total IgG were decreased in the serum of
Fosl2tg mice. In line with the presence of eosinophilia and
elevated IL-5 levels in Fosl2tg mice, we observed a significant in-
crease in IgE levels (Figure S2D).
Rag2-Dependent Immune Cells Drive Pathology in
Fosl2tg Mice
Altogether, our observation showed a strong systemic inflamma-
tory phenotype in Fosl2tg mice. We thus investigated whether
this phenotype resulted from a dysregulation of the adaptive im-
mune system. To address this point, we crossed Fosl2tg mice
with Rag2/ mice lacking B and T cells. Interestingly, none of
the Fosl2tgRag2/ mice developed dermatitis, even at the
ages of 16 weeks for females and 22 weeks for males (Figures
1F and S3A), whereas all Fosl2tg mice of these ages had to be
euthanized because of the severity of dermatitis. Fosl2tgRag2/
mice also did not show any signs of inflammation in other organs
(lungs, salivary glands), indicating that the systemic inflammation
observed in Fosl2tg mice is dependent on adaptive immunity
(Figures 1G, 1H, S3B, and S3C).
The absence of inflammation in Rag2/Fosl2tg mice pointed
to the involvement of T cells. We thus analyzed the T cell
compartment of Fosl2tg mice (gating strategy in Figure S4). In
7-week-old mice, before the appearance of inflammation,
Figure 1. Fosl2tg Mice Develop Systemic Inflammation
(A) Percentage of mice without skin lesions at different ages in weeks, for WT mice (females) and either Fosl2tg males or females (n = 10–12 each).
(B–D) Representative pictures of paraffin-embedded skin (B), lung (C), and liver (D) sections with hematoxylin and eosin (left) and CD45 (right) staining fromWT or
Fosl2tg mice (females, 16 weeks). Scale bars, 200 mm. (E) Multiplex analysis of cytokine levels in the serum of 17-week-old mice (males and females, n = 12).
(F) Representative picture of WT, Fosl2tg, and Rag2/Fosl2tg mice showing skin lesions around the eyes only in the Fosl2tg mouse.
(G) Representative pictures of submandibular salivary glands and lungs of WT, Fosl2tg, and Rag2/Fosl2tg mice showing enlargement (salivary gland) and
macroscopic lesions (lung) only in organs from Fosl2tg mice.
(H) Relative quantification of CD45 staining. Number of CD45-positive pixels was quantified in the entire sections and normalized to nuclei staining.
*p < 0.05, **p < 0.01, and ***p < 0.001, Mantel-Cox test (A), Mann-Whitney test, two-tailed (E), and Kruskal-Wallis test with Dunn’s multiple testing (H).




Figure 2. Increase of Effector T Cell Populations in Fosl2tg Mice
(A) Quantification of cell populations in the thymus of 7-week-oldWT and Fosl2tgmice. DN, double-negative (CD4CD8); DP, double-positive (CD4+CD8+); CD4
SP, CD4+ single-positive; CD8 SP, CD8+ single-positive. n = 5–8.
(B) Quantification of T cells in the spleens of WT and Fosl2tg mice at 7 or 16 weeks (n = 5–8).
(C) Analysis of the populations of activated (CD62LlowCD44hiFoxP3) and naive (CD62LhiCD44lowFoxP3) CD4+ cells and expression of CD25 in these pop-
ulations, from the lungs and spleens of WT or Fosl2tg mice (females, 16 weeks old).
(D) Quantification of the cell populations as in (C) (n = 5 mice per group).
(E) Staining for cytokines in CD4+ cells from WT and Fosl2tg mice (females, 16 weeks old). Splenocytes were stimulated for 12 h with PMA/ionomycin in the
presence of monensin and brefeldin A and stained for IFNg, IL-17A, IL-5, and IL-13.
*p < 0.05, **p < 0.01, and ***p < 0.001, two-way ANOVA with Dunnett’s multiple comparison (A and B) and Mann-Whitney test, two-tailed (D and E).
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in thymic cellularity (Figure 2A). There were also normal numbers
of CD4+ and CD8+ T cells in the spleen (Figure 2B).4 Cell Reports 31, 107826, June 30, 2020We then analyzed the phenotype of T cells in 16-week-old
Fosl2tg mice. We observed a significant drop in T cell numbers
in the spleen at 16 weeks during the development of systemic
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tion of effector CD62LlowCD44high cells (Figures 2C and 2D),
which also displayed increased CD25 expression, pointing to
T cell activation. We also found a strong infiltration of T cells in
the lungs and other affected organs. Naive T cells were also
decreased, with an increase in activated T cells in the lungs (Fig-
ures 2C and 2D).
Given the clear T cell activation, we analyzed the profile of cy-
tokines produced by these CD4+ T cells in Fosl2tg mice. There
was a decrease in the population of IFNg-secreting T cells and
no significant change in the population of IL-17A-producing cells
(Figure 2E; Figure S3D). However, we detected a strong increase
in both the proportions and numbers of IL-5- and IL-13-positive
cells, and the largemajority were positive for both cytokines (Fig-
ure 2E; Figure S3D). These data confirm the presence of T cell
activation in Fosl2tg mice with systemic inflammation and show
that these T cells are mostly Th2 polarized. This polarization is
consistent with the inflammation we observed, in particular pul-
monary eosinophilia and increased IgE and IL-5 in serum and
skin lesions. Concomitantly, we found a decrease in Th1 cells
with a strong drop in IFNg-producing CD4+ cells.
We also analyzed the CD8+ T cell compartment, which
showed a strong activation pattern, with a shift from a naive
(CD62LhiCD44low) to an activated (CD62LlowCD44hi) phenotype.
In the spleen of Fosl2tg mice, there was a decrease in the total
number of IFNg-positive cells (Figure S3E).
Fosl2 Represses Treg Development
A striking observation was that T cell activation in 16-week-old
mice was paralleled by a strong decrease of the CD25+FoxP3+
Treg population in percentages and absolute numbers (Fig-
ure 3A). Interestingly, this decrease of Tregs in the spleen,
inguinal lymph nodes (iLNs) and lungs in Fosl2tg mice was
already present at 3 weeks, before the appearance of T cell acti-
vation and before histological signs of organ inflammation (Fig-
ures 3B and 3C; Figures S5A–S5C). This confirmed that Treg
decrease was constitutive in Fosl2tg mice and not associated
with a relative accumulation of non-Treg cells
Our next step was to check whether this Treg deficiency arises
from an impairment of Treg development. Supporting this hy-
pothesis, we could show that tTregs were also strongly
decreased. Moreover, CD4+CD8CD25+FoxP3+ tTregs were
reduced but showed a normal pattern of CD44 andGITR expres-
sion (Figures 3D–3F and S5D). On the contrary, we observed that
CD4+CD8CD25+FoxP3 tTreg precursors were present in
normal amounts but showed an altered phenotype with a reduc-
tion of the CD44hiGITRhi population, suggesting abnormal Treg
development (Figures 3D–3F and S5D).
To further support a drop in tTreg production in Fosl2tg mice,
we analyzed the expression of the tTreg marker Nrp1 in the pe-
riphery of young Fosl2tg mice. Interestingly we did find a
decrease in the percentage of Nrp1-positive Tregs, consistent
with our observation of decreased tTreg development
(Figure S5E).
The abnormality in Treg development observed in the thymus
of Fosl2tg mice can explain the lack of Tregs in the periphery.
However, it could also result from abnormal Treg homeostasis,
with decreased proliferation or increased apoptosis. Thus, weanalyzed Treg proliferation in Fosl2tg mice. Surprisingly, Fosl2tg
Tregs were more proliferative than WT Tregs (Figure S7D). This
increase in Treg proliferation might represent a compensatory
mechanism in which the partially empty Treg niche promotes
the proliferation of the remaining Tregs. We also analyzed Treg
apoptosis in young Fosl2tg mice by staining the CD4+CD25+
population for annexin V. As expected, there were very few
apoptotic Tregs, and there was no increase in Fosl2tg mice (Fig-
ure S7E). Altogether, our data suggest that Treg homeostasis
does not contribute to the Treg phenotype of Fosl2tg mice.
We also assessed whether Fosl2 had an effect on the pheno-
type and suppressive function of Tregs. We thus analyzed
Fosl2tg Tregs for expression of several Treg-suppressive
markers. Although there was a slight decrease in PD1 expres-
sion, CTLA4 was slightly increased, with no major changes in TI-
GIT, GITR, or CD62L expression (Figure S6A). Overall, Fosl2 had
only a mild effect on Treg phenotype. We thus further addressed
suppressive capacities of both Fosl2-deficient and Fosl2-over-
expressing Tregs. Interestingly, they equally suppressed the
proliferation of responder T cells (Figure S6B). These data sug-
gest that Fosl2 is a repressor of Treg development but has little
effect on their phenotype or suppressive function.
As the reduced number of Tregs might be responsible for the
autoimmune phenotype of Fosl2tg mice, we tested whether
correction of the Treg deficiency would suppress the inflamma-
tory phenotype. To this end, we used a T cell transfer setup in
which total CD4+ T cells from young Fosl2tg mice were trans-
ferred to lymphopenic Rag2/ hosts. We found that transfer
of 1 3 106 purified CD4+ T cells from young Fosl2tg mice (5–
7weeks, before onset of T cell activation) intoRag2/ recipients
was sufficient to transfer the phenotype, as demonstrated by the
development of severe lung inflammation within 5 weeks post-
transfer (Figures 4A and 4B). This finding further supported the
contribution of T cells to the inflammatory phenotype. We then
tested the ability of co-transferred WT Tregs to suppress the
inflammation induced by Fosl2tg T cells. We first confirmed
that Treg transfer restored a normal proportion of Tregs in recip-
ient mice (Figure 4C). As expected, the supplementation of WT
Tregs also resulted in a dose-dependent prevention of lung
inflammation (Figures 4A and 4B). These data support the hy-
pothesis that the decrease of the Treg population is causing
the inflammation observed in Fosl2tg mice.
Fosl2 Restricts Treg Development in a Cell-Intrinsic
Manner
These experiments indicated that Fosl2 overexpression nega-
tively affects the development of Tregs. We then tested whether
this effect was bone marrow dependent. Irradiated Rag2/
recipient mice were injected with sex-matched and T cell-
depleted bone marrow from either WT or Fosl2tg mice. Mice
receiving Fosl2tg bone marrow developed colitis about 35 days
after transfer, as evidenced by weight loss, loose stools, reduc-
tion in colon length, and CD45 infiltrates in the colon (Figures 5A–
5E). Moreover, we observed a decrease of Treg percentages in
the thymus (Figure 5F). In the periphery, the lack of Tregs in re-
cipients of Fosl2tg bone marrow was even more pronounced
than in Fosl2tg mice (Figure 5G). Of note, Fosl2tg mice did not
develop colitis, a finding in contrast to our observation in miceCell Reports 31, 107826, June 30, 2020 5
Figure 3. Treg Deficiency and Reduced tTreg Development in Fosl2tg Mice
(A) Analysis of Treg populations (CD25+FoxP3+ and CD25FoxP3+) within the CD4+ T cells in the spleen of 16-week-old Fosl2tg and WT mice (n > 7).
(B) Analysis of Treg population (CD25+FoxP3+) within CD4+ T cells in the spleen, lung, inguinal lymph nodes (iLNs), and thymus inWT and Fosl2tgmice (females, 3–
6 weeks old).
(C) Quantifications of Tregs as in (B) (n = 3–8 mice per group).
(D) Analysis of CD25+FoxP3 Treg precursors or CD25+FoxP3+ Tregs in CD4 SP cells of the thymus of WT or Fosl2tg mice (3–6 weeks old).
(E) Analysis of GITR, FoxP3, CD44, and CD25 expression in tTregs from WT or Fosl2tg mice (females, 3–6 weeks old).
(F) GITR and CD44 expression in either CD25+FoxP3 Treg precursors or CD25+FoxP3+ Tregs in CD4 SP cells of the thymus of WT or Fosl2tgmice (3–6 weeks old).
*p < 0.05, **p < 0.01, ***p < 0.001, Mann-Whitney test, two-tailed (A, C, and F).
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cipients represent a lymphopenic environment, which, com-
bined with the Treg deficiency associated with Fosl2tg bone
marrow, explains the development of colitis.
To further support these findings, we transferred WT bone
marrow into Rag2/ Fosl2tg mice, a setup in which WT thymo-
cytes develop in a Fosl2tg thymus. These chimeric mice did not6 Cell Reports 31, 107826, June 30, 2020develop colitis and had normal Treg populations in the thymus
and in the periphery, confirming a bone marrow-dependent
phenotype (Figures 5A–5G). Taken together, these data showed
that the effect of Fosl2 on Treg development is bone marrow
dependent.
Next, we addressed whether Fosl2 inhibits Treg development
in a cell-intrinsic manner. To this end, we performed a mixed
Figure 4. WT Tregs Suppress Lung Inflammation Induced by Fosl2tg CD4+ T Cells
(A) Rag2/ mice (10–14 weeks old) received by intravenous (i.v.) injection 13 106 CD4+ cells fromWT mice or 13 106 CD4+ cells from Fosl2tg mice (4–6 weeks
old) either alone or together with 3 3 105 or 106 Tregs from WT mice. Lungs were harvested 5 weeks after transfer, and paraffin-embedded lung sections were
stained for CD45. Representative pictures of an entire lobe (left; scale bar, 1 mm) and higher magnification (right; scale bar, 100 mm).
(B) Relative quantification of CD45 staining of the lungs as in (A). Number of CD45-positive pixels was quantified in the entire lung sections and normalized to the
total surface of the lung sections.
(C) FoxP3+ cells in the spleens of recipients mice 5 weeks post-transfer show reconstitution of the Treg population by co-transfer of WT Tregs.
*p < 0.05 and **p < 0.01, Kruskal-Wallis test with Dunn’s multiple testing.




Figure 5. Fosl2 Effect on Tregs Is Bone Marrow Dependent
(A–G) Rag2/ recipients (10–14 weeks old) received bonemarrow from either WT or Fosl2tgmice, andRag2/Fosl2tg recipients received bonemarrow fromWT
mice. Body weight changes in mice after transfer were recorded for 35 days (n = 5 or 6). (B) Representative pictures of colons at day 35 post-transfer. (C) Colon
lengths as in (B). (D) Representative pictures of paraffin-embedded sections of the colon of mice as in (B) stained for CD45; scale bar, 1 mm. (E) Relative
quantification of CD45 staining of the colon as in (D) (n R 5). (F and G) Percentage of CD25+FoxP3+ within the CD4+CD8 population in the thymus (F) and the
spleen (G) of mice at day 35 post-transfer (n R 5).
(legend continued on next page)




Figure 6. Deletion of Fosl2 in T Cells Re-
duces EAE Severity
(A) Fosl2fl/flCD4-Cre+ mice or Fosl2fl/+CD4-Cre+
mice received a single immunization with MOG
peptide to induce EAE. Mice were then scored for
symptoms severity by a blinded observer. Data
are representative of two different experiments
with five mice per group in each.
(B) Treg and Teff populations of CD4+ cells were
analyzed in the brain of EAE mice 15 days after
immunization.
(C) Ratio of effectors to Treg cells in the brain as
in (B).
(D) Percentage of Nrp1+ Tregs in the brain of EAE
mice as in (B).
(E) Treg populations in the inguinal lymph nodes of
EAE mice 5 or 15 days after immunization.
Expression of Treg markers PD1, GITR, Helios,
and CTLA4 and activation marker CD44 were
analyzed. Fold change of expression in Fosl2/
Tregs compared with control is represented.
(F) Expression of activation markers CD25 and
CD62L by FoxP3CD4+ T cells in the lymph nodes
of EAE mice 5 days after immunization.*p <




OPEN ACCESSbonemarrow transfer, in whichRag2/ recipients received a 1:1
mix of WT (CD45.1) and Fosl2tg (CD45.2) sex-matched and
T cell-depleted bone marrow. Interestingly, there was no overt
colitis in these mice compared with recipients of pure Fosl2tg
bone marrow (Figure S7A), suggesting that WT bone marrow
had a dominant protective effect. Strikingly, the proportion of
FoxP3+ cells was much lower in Fosl2tg CD4 SP cells compared
with WT CD4 SP cells, confirming a cell-intrinsic effect of Fosl2.
Here again, the proportion of FoxP3+ cells of Fosl2tg origin in the
periphery was much lower than in the Fosl2tg mice (Figures 5H
and 5I). We also directly compared the T cell development of
WT versus Fosl2tg cells in this mixed setup, and, confirming
our data in Fosl2tg mice, we did not detect a significant effect
of Fosl2 on T cell development (Figures S7B and S7C). Alto-
gether, we showed that Fosl2 overexpression inhibits, in a cell-
intrinsic manner, tTreg development.
Fosl2 Deletion in T Cells Reduces Autoimmunity
Of note, mice with a T cell-specific Fosl2 deletion were reported
to have a normal phenotype, without changes in T cells and Treg(H) Rag2/ recipients (10–14 weeks old) received mixed 1:1 bone marrow (WT, CD45.1; Fosl2tg, CD45
spleen within CD4+ cells and within the CD4+CD8 populations in the thymus of either CD45.1 (WT) or CD45
transfer.
(I) Percentages of FoxP3+ cells within CD4+ (iLN and spleen) or within CD4+CD8 (thymus) cells as in (H).
*p < 0.05, **p < 0.01, and ***p < 0.001, two-way ANOVA with Tukey’s multiple comparison test (A), Kruskal-W
Wilcoxon test, two-tailed (I).development or T cell populations in the
periphery (Lawson et al., 2009). We could
confirm these findings in our Fosl2fl/fl
CD4-cre mice (Figures S8A and S8B).
To further address the effect of Fosl2deletion in T cells, we first tested whether Fosl2ko T cells had
different T cell development of homeostatic properties. To this
end, we generated Fosl2ko-WT bone marrow chimera mice. In
this setup, we observed a normal population of Fosl2/ Tregs
compared with WT (Figure S9A).
We next addressed whether a phenotype could be observed
outside of steady-state conditions. We thus induced experi-
mental autoimmune encephalomyelitis (EAE) in Fosl2fl/flCD4-
cre mice to see if Fosl2 deletion altered autoimmunity. Strikingly,
Fosl2 deletion significantly reduced the severity of EAE, which
mirrored our observations of spontaneous autoimmunity in
Fosl2tg mice (Figure 6A).
We further analyzed the composition of the T cell population in
mice with EAE. There was no significant change in the Treg
population in the brains of Fosl2-deficient EAE mice. There was
a tendency toward a lower proportion of effector cells, and a lower
Teff-to-Treg ratio, which might be due to the overall decreased
severity of inflammation in Fosl2ko mice (Figures 6B and 6C).
Interestingly, there was an increase in the expression of the tTreg
marker Nrp1 in the brains of Fosl2-deficient mice (Figure 6D). This.2). Representative plot of FoxP3 staining in the
.2 (Fosl2tg) origin in recipient mice at day 35 post-
allis test with Dunn’s post hoc analysis (B–D), and
Cell Reports 31, 107826, June 30, 2020 9
Article
ll
OPEN ACCESSfinding is supportive of our observation of reduced tTregs in
Fosl2tg mice. We then hypothesized that Fosl2 deficiency might
affect the induction phase in EAE, andwe analyzed the population
of Tregs in the iLNs5 days after immunization. There,weobserved
an overall tendency toward an increase in all Treg-suppressive
markers that we analyzed (Figures 6E, S9B, and S9C). On the
other hand, these markers were decreased later during the dis-
ease, at a stagewhenFosl2komice had reduced disease severity.
To address the possibility that reduced EAE severity is due to a
reduction in T cell activation, we first tested in vitro the effect of
Fosl2 on T cell activation. We did not obverse any significant
changes in the expression of activation markers or proliferation
of anti-CD3/anti-CD28 stimulated T cells upon overexpression
or deletion of Fosl2 (Figures S8C and S8D). We also did not
observe a change in conventional T (Tconv) cell activation
markers in EAE mice (Figure 6F).
We thus demonstrate that Fosl2 deficiency in T cells results in
a clear reduction in autoimmunity, with a slight modification of
the Treg population and an increase in Nrp1+ Tregs.
Fosl2 Is TCR Induced and Reduces FoxP3 Expression
To address how Fosl2 affects Treg development, we first
analyzed Fosl2 expression in T cells. Whereas Fosl2 protein
could not be detected in unstimulated naive T cells, Fosl2
mRNA was rapidly upregulated 30 min after TCR stimulation
and reached a plateau thereafter (Figure S10A). This resulted in
a strong upregulation at the protein level after 24 h (Figure 7A).
Expression of Fosl2 was delayed in comparison with Fos and
Jun. To address whether Fosl2 was also induced by TCR
signaling in developing thymocytes, Fosl2 expression was quan-
tified in CD69 and CD69+ double-positive (DP) thymocytes,
corresponding to earliest TCR signaling in thymocytes. There
was a strong upregulation of Fosl2 mRNA in CD69+ DP thymo-
cytes, confirming that Fosl2 expression is induced by TCR (Fig-
ure 7B), a finding supported by available proteomic datasets
(Tan et al., 2017).
As Fosl2was reported to be differentially expressed in Th1 and
Th2 cells, and is a Stat3 target gene during Th17 induction (Tri-
pathi et al., 2017; Lund et al., 2007), we analyzed how polarizing
conditions would further affect Fosl2 protein expression. We
stimulated CD4+ T cells for 24 h with anti-CD3 and anti-CD28
monoclonal antibodies (mAbs) under Th0, Th1, Th2, Th17, and
iTreg conditions. There was little difference in Fosl2 expression
during Th cell polarization, with a slightly lower expression in
Th2 (Figure 7C), but Fosl2 expression was decreased under
iTreg conditions. The reduced expression of Fosl2 was
confirmed in Tregs and their precursors isolated from the thymus
(Figure 7D).
To support our findings and addresswhether Fosl2 expression
pattern is similar in humans, we used an available dataset of RNA
sequencing (RNA-seq) in multiple immune cell populations
sorted from human healthy blood (Schmiedel et al., 2018). Inter-
estingly, there was a clear upregulation of Fosl2 after TCR stim-
ulation, similar to what we observed in mice (Figure 7E). More-
over, Fosl2 expression was lower in Tregs, especially naive
Tregs, with Th1 and Th17 showing higher expression (Figure 7E).
We also found that compared with other AP1 members, the
expression pattern of Fosl2 was unique. Indeed, Fosl2 shows10 Cell Reports 31, 107826, June 30, 2020the most differential expression in the different T cell subsets
among all AP1 proteins and is, with Fosl1, the only one still upre-
gulated on mRNA level after 4 h (Figure S10B).
We next investigated the mechanisms by which Fosl2 re-
presses Treg development. As Fosl2 target genes in T cells
were so far unknown, we addressed the effect of Fosl2 on the
transcriptome of T cells during T cell activation.
Sorted naive (CD62LhighCD44lowCD25) CD4+ T cells from
WT, Fosl2tg, or Fosl2fl/flCD4-cre+ mice (hereafter Fosl2/)
were stimulated in vitro for 24 h with anti-CD3 and anti-CD28
mAbs. The mRNA expression profile was analyzed using RNA-
seq.
We first confirmed the efficacy of Fosl2 overexpression and
depletion by analyzing reads over the Fosl2 loci (Figure S10C).
We ran pairwise comparisons to establish a list of differentially
expressed genes (corrected p < 0.05) among WT, Fosl2tg, and
Fosl2/. We then filtered genes with fold changes > 1.5 and
applied a false discovery rate of 5%. We further focused on
genes with opposite regulation in Fosl2tg versus Fosl2/. This
strategy yielded 189 Fosl2-regulated genes (Figure 7F).
FoxP3 was one of the top differentially regulated genes, with a
clear downregulation in Fosl2tg cells and upregulation in Fosl2/
cells (Figure 7G). This result supported our hypothesis and
confirmed that the level of Fosl2 expression during T cell activa-
tion controls the expression of FoxP3. We then assessed
whether Fosl2 also affected expression of FoxP3 on the protein
level. We analyzed the percentage of FoxP3-positive cells after
3 days of activation without or with 1 ng/mL TGF-b. In the
absence of TGF-b, there were very few FoxP3-positive cells,
with, however, a small increase in FoxP3-positive cells in
Fosl2/ cells (Figure 7G). In contrast, in the presence of TGF-
b, Fosl2tg cells had a clear reduction in FoxP3, confirming that
Fosl2 also repressed iTreg induction. To further address whether
Fosl2 could affect FoxP3 expression, we compared FoxP3mean
fluorescence intensity (MFI) in mixed bone marrow chimera mice
that received a mix of either WT and Fosl2tg or WT and
Fosl2fl/flCd4-cre+ bone marrow. In this setup, WT cells serve as
an internal control to precisely compare the level of FoxP3
expression (Figure 7I). We confirmed that Fosl2 overexpression
reduced FoxP3 expression in Tregs. In Fosl2/ Tregs, there
was also a slight increase in FoxP3 MFI compared with WT,
although the magnitude of this change was very small (Figure 7I).
Fosl2 also repressed the expression of Nr4a2, IRF8, Ccl1, and
Ccr8 (Figure S10D), four genes involved in Treg differentiation or
function (Sekiya et al., 2011; Lee et al., 2016; Barsheshet et al.,
2017).
To further analyze the effects of Fosl2 on the T cell transcrip-
tome, we ranked Fosl2-regulated genes using the sum of fold
changes in Fosl2tg and Fosl2/ T cells compared with WT. We
then ran a pre-ranked gene set enrichment analysis (GSEA) to
compare our gene set with previously published immunologic
gene sets of theGSEAdatabase (Subramanian et al., 2005;Moo-
tha et al., 2003). Interestingly, among the first ten datasets en-
riched in our gene list, three were linked to FoxP3-transduced
cells and twowith tTreg development. In particular, four datasets
reached a false discovery rate of 0.05 (Figure S10F). Strikingly,
the most significant dataset showed a negative correlation be-
tween Fosl2-promoted genes and the tTreg gene signature
Figure 7. Fosl2 Controls FoxP3 Expression and Treg Signature
(A) Sorted naive CD4+CD25CD62LlowCD44hi T cells were stimulated and Fosl2 expression was analyzed by immunoblot. Representative of n = 3 biological
replicates.
(B) qPCR analysis of Fosl2 expression in thymocyte populations (DP, double-positive CD4+CD8+), normalized to GAPDH; n = 5 biological replicates.
(C) WT CD4+ T cells were stimulated for 24 h with anti-CD3 (2 mg/mL) and anti-CD28 (2 mg/mL) mAbs in Th0-, Th1-, Th2-, Th17-, or iTreg-polarizing conditions.
Western blot with GAPDH as loading control. Representative of n = 3 biological replicates.
(D) Fosl2 mRNA expression in FoxP3+CD25+ (tTreg) and FoxP3CD25+ tTreg precursors compared with single-positive (SP4) thymocytes in FoxP3-GFP mice.
(E) Fosl2 expression in human healthy T cells sorted from blood (publicly available dataset; Schmiedel et al., 2018).
(F) Gene expression as FPKM in Fosl2tg versus Fosl2/ T cells. Sorted naive (CD62LhighCD44lowCD25) CD4+ T cells fromWT, Fosl2tg, or Fosl2fl/flCD4-cre+ mice
(referred to as Fosl2/) were stimulated for 24 h with anti-CD3 and anti-CD28. Genes repressed by Fosl2 (i.e., downregulated in Fosl2tg cells and upregulated in
Fosl2/ cells) are highlighted in red. Genes promoted by Fosl2 are highlighted in blue.
(G) FPKM expression of FoxP3 in our RNA-seq experiment and FoxP3 expression by fluorescence-activated cell sorting (FACS) in Fosl2tg and Fosl2/ T cells
after 3 days of stimulation with or without TGF-b.
(H) Enrichment plot for the dataset GSE7460.
(I) Comparison of FoxP3 expression (MFI) by FACS in Tregs of WT, Fosl2tg, or Fosl2fl/flCD4-cre+ origin in mixed bone marrow transferred mice.
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expression can repress the expression of FoxP3 and of Treg-
specific genes during the development of Tregs.
DISCUSSION
Tregs are crucial in maintaining homeostasis and tolerance in the
immune system. Alterations in pathways controlling the develop-
ment and function of Tregs have been proposed to be important
pathomechanisms in autoimmune and auto-inflammatory dis-
eases. Here we have discovered that the AP1 transcription factor
Fosl2 is central to the control of autoimmunity and is involved in
Treg development.
Fosl2tg mice showed similarities with the phenotype of fully
Treg-deficient Scurfy and DEREG mice and the disease devel-
oped by IPEX patients. However, Fosl2tg animals survived longer
and had a less severe phenotype, which might be explained by
the partial Treg deficiency in Fosl2tg animals (Brunkow et al.,
2001; Godfrey et al., 1991; Lahl et al., 2007). The inflammation
observed in the lungs, skin, liver, pancreas, and salivary glands
is also strikingly similar to what was observed in mice with
Treg-specific genetic disruptions (Miyazaki et al., 2014) and is
reminiscent of the organ inflammation observed in several auto-
immune diseases.
Our data in Fosl2tg mice suggest that the reduction of the Treg
population is caused mostly by a decrease in tTreg develop-
ment. We indeed observed a reduction in the tTreg population,
while the composition of the tTreg precursor population was
altered. However, the increased proliferation rate of Fosl2tg
Tregs observed in T cell transfer or bone marrow transfer exper-
iments suggests that under certain circumstances, Fosl2 might
also control Treg homeostasis.
Our data also support the idea that Fosl2 can affect the
expression of FoxP3 on bothmRNA and protein levels. However,
we cannot definitely establish whether Fosl2’s control of FoxP3
is direct or indirect. For example, we identified in our RNA-seq
experiment a set of genes modulated by Fosl2 and known to
contribute to Treg biology. In particular, Fosl2 repressed the
expression of Nr4a2 and IRF8, two transcription factors involved
in Treg differentiation or function (Sekiya et al., 2011; Lee et al.,
2016). Furthermore, Fosl2 repressed Ccl1 and its receptor
Ccr8. Interestingly, Ccr8+ Tregs have been shown to be impor-
tant in immune regulation through autocrine stimulation of Tregs
by Ccl1 (Barsheshet et al., 2017).
On the other hand, AP1 is known to function as a network of
heterodimers, and the Fos/Jun dimers in particular are known
to promote the expression of FoxP3 through direct binding to
FoxP3 promotor (Ogawa et al., 2014). One possible mechanism
would thus be that Fosl2, when forming dimers with other AP1
members, can directly interact with FoxP3 locus and repress
transcription. This could counter, or compete with, the effects
of other AP1 dimers such as Jun/Fos, which normally promote
FoxP3 expression.
Such a mechanism of action can also be discussed in light of
our observations in T cell-specific Fosl2-deficient mice. Indeed,
we did not observe a phenotype under steady-state conditions,
which would indicate that Fosl2 is not involved in T cell biology.
This apparent lack of phenotype is not completely surprising12 Cell Reports 31, 107826, June 30, 2020given the complex and partly redundant mode of action within
the AP1 family. There have indeed been several examples of
functional redundancies in the AP1 family and in particular
among the Fos proteins. Fos is a good example of this, as its
role in T cell biology is well described, with the Fos/Jun AP1
complex, for example, being key in the induction of IL-2 or
FoxP3 expression (Ogawa et al., 2014; Ochi et al., 1994; Jain
et al., 1992). However, as for Fosl2 in our study, T cell-specific
Fos-knockout mice have no apparent phenotype with normal
T cell development and normal T cell function in the periphery
(Jain et al., 1994). Fos-knockout T cells also express normal
amounts of IL-2 despite the important role of c-Fos in IL-2
expression. On the contrary, c-Fos overexpression leads to a
strong (>5-fold) increase in IL-2 expression (Ochi et al., 1994),
indicating that overexpression is an important tool to highlight
AP1 protein functions. Further supporting this, replacing c-
Fos gene by Fosl1 in mice has no phenotypic consequences,
confirming that c-Fos and Fosl1 have maintained a functional
equivalence (Fleischmann et al., 2000). We thus think that as
for Fos, other AP1 members can partially compensate the
loss of Fosl2 and explain our observations in Fosl2fl/flCD4-cre
mice under steady state.
Importantly, our findings in the EAE model, in which we
observed a clear reduction in autoimmunity upon T cell-specific
deletion of Fosl2, confirm that Fosl2 is important in T cell-medi-
ated control of tolerance. Under these autoimmune conditions,
which represent a dynamic situation with T cell activation, it
seems that the function of Fosl2 is not fully compensated,
enabling us to observe Fosl2 contribution to AP1-mediated con-
trol of T cell tolerance. Our findings thus suggest that in T cells,
Fosl2 has both a set of unique functions, visible in our EAE exper-
iments, and redundant functions, which mitigate the phenotype
of Fosl2 depletion. It would be interesting to further dissect the
contribution of other AP1members to understandwhich oneme-
diates this redundancy. Of note, there is so far no report of the
function of Fosl1, which has an 85% homology to Fosl2, in
T cells. Fosl1 might thus be a good candidate to investigate
the redundancy with Fosl2 functions.
Interestingly, we also found that Fosl2tgmice develop a strongly
Th2-polarized autoimmune response. This polarizationmight indi-
cate an additional function for Fosl2 in effector T cell polarization.
This is in line with other observations indicating the contribution of
AP1 members to Th cell biology (Carr et al., 2017). Moreover, this
Th2 polarization might partly explain the organs affected by auto-
immunity in Fosl2tgmice. The lungs and skin, which are heavily in-
flamed in Fosl2tg mice, are indeed prone to Th2 inflammation,
while the colon, for example, which is often affected by Th1-
and Th17-dependent inflammation in the absence of Tregs, is
not affected in our mice (Feng et al., 2011).
We have found that Fosl2 is a TCR-induced gene in both thy-
mocytes and mature T cells, with lower expression in Tregs.
Interestingly this was common to both human and mice. This
suggests that Fosl2’s ability to influence inflammation and auto-
immunity could also be relevant in humans. Supporting that fact,
several GWASs reported association of a SNP within the pro-
moter of Fosl2 with risk for inflammatory bowel disease (IBD)
and allergic diseases (Jostins et al., 2012; Liu et al., 2015; Ye
and McGovern, 2016; Ferreira et al., 2019). Moreover, this SNP
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IBD patients (Di Narzo et al., 2016), indicating that Fosl2 risk as-
sociation is mediated by immune cells. Also supporting the clin-
ical relevance of Fosl2 expression in Tregs, it was found that
Fosl2 is a determinant of a highly suppressive subpopulation of
Tregs in humans, which are enriched in the lamina propria of
Crohn’s disease patients and which support wound repairs in
the mucosa (Povoleri et al., 2018).
In summary, we present significant evidence that Fosl2 is an
important AP1 member involved in the repression of Treg devel-
opment, with direct effects on autoimmunity and inflammation.
Fosl2tg mice will also constitute a valuable model to study how
Treg deficiency triggers autoimmunity and inflammatory organ
involvement or to address sex differences in susceptibility to im-
mune tolerance breakdown.
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(2003). PGC-1alpha-responsive genes involved in oxidative phosphoryla-
tion are coordinately downregulated in human diabetes. Nat. Genet. 34,
267–273.
Ochi, Y., Koizumi, T., Kobayashi, S., Phuchareon, J., Hatano, M., Takada,
M., Tomita, Y., and Tokuhisa, T. (1994). Analysis of IL-2 gene regulation in
c-fos transgenic mice. Evidence for an enhancement of IL-2 expression in
splenic T cells stimulated via TCR/CD3 complex. J. Immunol. 153, 3485–
3490.
Ogawa, C., Tone, Y., Tsuda, M., Peter, C., Waldmann, H., and Tone, M. (2014).
TGF-b-mediated FoxP3 gene expression is cooperatively regulated by Stat5,
Creb, and AP-1 through CNS2. J. Immunol. 192, 475–483.
Owen, D.L., Mahmud, S.A., Sjaastad, L.E., Williams, J.B., Spanier, J.A., Si-
meonov, D.R., Ruscher, R., Huang, W., Proekt, I., Miller, C.N., et al. (2019).
Thymic regulatory T cells arise via two distinct developmental programs.
Nat. Immunol. 20, 195–205.
Povoleri, G.A.M., Nova-Lamperti, E., Scottà, C., Fanelli, G., Chen, Y.C.,
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Materials Availability
Fosl2tg mice are available through MTA as rights belongs to Sanofi.
This study did not generate new unique reagents.
Data and Code Availability
Data from our RNA seq experiment have been deposited in the GEO database: RNA-seq data accession code: Gene Expression
Omnibus: GSE132313.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
C57Bl6 and Rag2/ mice were purchased from Jackson Laboratory. Fosl2fl/fl mice were obtained from Aline Bozec (University of
Erlangen) and rederivated by embryo transfer, CD4-cre and FoxP3-GFP mice were obtained from Burkhard Becher (University of
Zurich), Ly5.1 mice were obtained fromOnur Boyman (University Hospital Zurich). All mice were housed in pathogen free conditions.
We received approval for all animal experiments from the Cantonal Veterinary Office Zurich.
Fosl2tg mice were generated by Arun Subramaniam (Sanofi-Genzyme). A vector containing the murine Fosl2 gene (Exons 1 to 4,
corresponding introns, and truncated UTRs) under the control of the MHCI promotor H2Kb was randomly inserted into the genome
(Figure S1A). The eGFP sequence was inserted in frame after the Fosl2 transgene as a marker. To avoid generation of a Fosl2-eGFP
fusion protein, a self-cleaving peptide T2A (Thosea asigna virus 2A) was inserted between the two coding sequences, creating a bi-
cistronic transgene. The 2A self-cleaving peptide induces cleavage of the amino-acid chain during translation, giving rise to two
separate proteins without the need of adding an IRES sequence.
We used the following primers for genotyping:
Fosl2tg mice Forward: ‘‘GCACGACTTCTTCAAGTCCGCCATGCC’’





The Rag2/ mice genotype was confirmed by flow cytometry staining of T cells in blood samples. Fosl2tg were also phenotyped
by analyzing GFP expression in peripheral blood mononuclear cells (PMBCs) by flow cytometry.
Age of the mice used in the different experiments is indicated in the Figure legends. Whenever an experiment was performed using
onlymales or females, this is alsomentioned in figure legends or themethod section. All mice in this study have been backcrossed for
more that 10 generation on a C57Bl6/J background. Mice were housed in pathogen free conditions.
METHOD DETAILS
Experimental Autoimmune Encephalomyelitis
Age- and sex-matched 6-12 week old mice were used for all experiments. Mice were immunized with 200mg MOG35-55 emulsified in
CFA and treatedwith 200ng Pertussis toxin (i.p.) on the day of immunization and again two days later. Miceweremonitored for weight
loss and scored by a blinded experimenter for clinical symptoms for 15 days.
Flow cytometry
For all flow cytometry and cell sorting experiments, we used PBS with 1% FCS and 1mM EDTA (FACS buffer). Spleen and lymph
nodes were gently smashed through a 70 mm cell strainer. Cells were washed once in FACS buffer and red blood cells were lysed
using RBC lysis buffer (Biolegend).
The following antibodies were used for flow cytometry and cell sorting (dilutions 1:100 to 1:400). From eBioscience, Biolegend or
BD: CD25 (clone PC61.5), CD44 (clone IM7), CD62L (clone MEL-14), CD69 (clone H1.2F3), CD45.1 (APC-eFluor 780, clone A20),
CD45.2 (clone 104), Thy1.2 (clone 53-2,1), FoxP3 (clone FJK-16 s), Ki67 (clone SolA15), CD3 (clone 17A2), CD4 (clone GK1.5 or
RM4-5), CD8 (clone 53-6, 7), Helios (clone 22F6), Neuropillin1 (clone 3E12), CD19 (clone 1D3 or 6D5), CD45 (clone 30-F11),Cell Reports 31, 107826, June 30, 2020 e2
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29F.1A12). For staining of FoxP3, we used the FoxP3 staining buffer set (eBioscience).
Exclusion of dead cell was based on Fixable viability dye eFluor 780 (eBioscience) Zombie Yellow (Biolegend) or Propidium Iodide
(eBioscience). For compensation, we used cells or UltraComp eBeads (Invitrogen) and compensation was calculated at the time of
acquisition on the BD FACSDiva software. For cell quantification, we used Precision Count Beads (Biolegend).
All samples were acquired on the BDLSRFortessa II or FACSymphony flow cytometer using BDFACSDiva software. Cell sorting was
done on BDFACSAria III cell sorter. Data analysis was performed on FlowJo 10.0.8r1. Example of gating strategy is shown in Figure S4.
Histology and Immunohistochemistry
For histology, we perfused the circulatory system immediately after euthanasia by opening the right atria and slowly injecting 10ml of
PBS in the right ventricle using a 24G needle. Entire organs were then collected, washed in PBS and fixed for 16 h in 4% parafor-
maldehyde in PBS. Tissues were then washed in distilled water and transferred to 50% ethanol. Organs were dehydrated by 3
one h incubations in 80% ethanol, followed by 3 one h incubations in 96% ethanol, followed by 2 one h incubations in 100% ethanol.
Tissues were then cleared twice in xylene for one h and subsequently kept in a 56Cparaffin bath, twice, for 3 h. After paraffin embed-
ding, 4 mm thick sections were placed on Superfrost Plus slides (Thermo Scientific) and dried overnight.
For all subsequent stainings, sections were de-paraffinised by washing three times in xylene for 10min and rehydrated by sequential
incubations in 100%, 100%, 96% and 80% ethanol solutions for 3 min each. Sections were finally incubated for 5 min in distilled water.
For H&E staining, rehydrated sections were incubated for 10 min in Mayer’s hematoxylin solution (J.T Baker) and rinsed for 10 min
in running tap water. Sections were stained for one min in eosin 1% solution (Reactolab) and quickly rinsed in distilled water before
dehydration with increasing ethanol concentration.
For immunohistochemistry, antigen retrieval was performed on rehydrated sections. In brief, sections were boiled in citrate buffer
(10mMCitrate, 0.05% tween, pH = 6) with amicrowave, and further incubated at 95C in an oven for 15min. Sectionswere left to cool
down and washed in PBS. To block endogenous peroxidases, sections were incubated 15 min in 3%H2O2 solution and rinsed twice
in PBS-Tween for 5 min. To block unspecific antibody binding, sections were incubated for one h in blocking solution (10% goat
serum in Background Reducing Antibody Diluent from Dako). Endogenous biotin was blocked using the Avidin-Biotin Block kit
(from Vector Laboratories). The primary antibody was incubated overnight at 4C followed by two washings in PBS-Tween for
5 min. The biotinylated secondary antibody was incubated for 30 min at room temperature. After washing twice with PBS-Tween
for 5 min, sections were incubated for 30 min with VECTASTAIN Elite ABC solution (Vector Laboratories) and washed twice in
PBS for 5 min. Staining was developed using DAB (from Vector Laboratories) followed by a counterstaining of nuclei for 1 min in
Mayer’s hematoxylin solution (J.T Baker). All stainings were mounted using Pertex mounting medium.
Cell culture
WeusedDMEMcontaining high glucose (4.5 g/l), 10%heat inactivated FCS, pyruvate (0.11 g/l), L-Glutamate (0.58 g/l) supplemented
with MEM Vitamins solution (GIBCO), MEM Non-essential amino acids (GIBCO) and b-mercaptoethanol (50mM).
RT-qPCR
RNAwas extracted from cell pellets usingQuick RNAMicroPrep /ZymoResearch). RNAwas quantified using the Nano-dropND1000
(Thermo Fisher). Two hundred ng of RNA was then reverse transcribed using the transcriptor First Strand cDNA synthesis kit (Roche)
with oligo-dT primers. qPCR was performed using SYBR green GoTaq qPCR master mix (Promega) on Agilent Startagen Mx3005P
qPCR system. Relative expression was calculated using the DDCt method.
Western-blot
For cell lysis, we used RIPA buffer (Sigma-Aldrich) supplementedwith protease and phosphatase inhibitor tablets (EASYpack Protease
inhibitor cocktail, PhosphoSTOPboth fromSigma-Aldrich), sample reducing agent (Life Technologies) andPierce universal nuclease for
DNA digestion (Thermo Scientific). Cells were lysed at 20million cells per ml of lysis buffer; mixed with 4x LDS loading buffer (Life Tech-
nologies) and boiled at 95C for 5min. Electrophoresis andwet transferweremade using theMini Protean system fromBioRad. Lysates
were separated with a 12% SDS-PAGE and transferred on nitrocellulose membranes. Membranes were blocked for 1 h with 5% milk
proteins in TBS-Tween before incubationwith the primary antibody overnight at 4C. HRP conjugated secondary antibodies were incu-
bated for 45 min at room temperature (1:10000 Jackson Immunolabs). We used SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific) for development on the Fusion Fx (Vilber). For protein size assessment, we used the PageRuler Plus protein ladder
(Thermo Scientific). We screened available anti-Fosl2 antibodies using our Fosl2tg and Fosl2/ cells to validate specificity. The mono-
clonal antibody REY146C (1:1000) fromMerkMillipore was selected as it showed increased signal in overexpressing cells and no signal
was detected in ko cells (Figure S1D). Other antibodies were from Cell Signaling and were used at 1:1000: phosphor-c-Fos (clone
D82C12), total c-Fos (clone 9F6), c-Jun (clone 60A8) and GAPDH (clone 14C10).
ELISA and multiplex
For quantification of immunoglobulins, cytokines, and chemokines, we collected blood from the vena cava immediately after eutha-
nasia of wt or Fosl2tg mice. Serum was collected after spin down of the blood and snap frozen for later analysis. Cytokines, chemo-e3 Cell Reports 31, 107826, June 30, 2020
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parameter multiplex assay or individual ELISA.
Cytokines and chemokines analyzed included G-CSF, GM-CSF, IFN-g, IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12
(p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1a, MIP-1b, MIP-2, RANTES, TNF-a (Millipore MAP mouse cyto-
kine/chemokine magnetic kit, cat# MCYTOMAG 70k PMX). The assay was performed in 96 well plates in duplicates following man-
ufacturer’s protocol and data acquired on a Milliplex analyzer (Luminex SD). IgG and IgE levels were quantified in the serum of
16 week old females using Ready-SET go Elisa kit for mouse from eBioscience. The assay was performed in duplicates.
RNA-sequencing
Total RNA was isolated from the samples using QIAGEN’s RNeasy Mini Kit. RNA integrity number values ranged from 8.1 to 10.0.
Directional Poly-A RNA-seq libraries were prepared and sequenced as PE42 (42-bp paired-end reads) on Illumina NextSeq 500
to a depth of 35-64M read pairs. The ‘‘TopHat’’ algorithm was used to align the reads to the mm10 genome. The alignments (32-
60M aligned pairs) in the BAM files were further analyzed using the Cufflinks suite of programs (running consecutively: Cufflinks
/Cuffcompare/Cuffdiff) (Trapnell et al., 2010, Trapnell et al., 2013). Cufflinks was run using themm10-genes as a reference data-
base. By doing so, the output shows the known genes with their RNA-Seqmetrics (as FPKM=Fragments Per Kilobase of exonmodel
perMillionmapped fragments), but novel transcripts are not identified. The 9 (33 3 replicates) cufflinks outputs were compared using
cuffdiff.
We obtained a total of 2679 genes for control versus Fosl2tg, 1150 genes for control versus Fosl2/ and 3510 genes for Fosl2tg
versus Fosl2/. In total, there were 4123 genes differentially regulated in a least one of the pairwise comparisons.
We then filtered genes with a fold change >1.5, and with consistent (opposite) change between Fosl2tg and Fosl2/ cells. We thus
selected the genes, which showed an upregulation in Fosl2tg and a downregulation in Fosl2/ and the genes showing a downregu-
lation in Fosl2tg and an upregulation in Fosl2/. For enrichment analysis, we used the Gene Set Enrichment Analysis software.
Imaging and immunohistochemistry quantification
Images were acquired on an Olympus BX53 microscope with a DP80 camera.
For relative quantification of immunohistochemistry signals, we scanned the entire slide to avoid potential bias in selecting a region
of interest for the analysis. DAB (brown) and hematoxylin (nuclei signal, blue) signals were separated using the Color Deconvolution
plugin of ImageJ. One threshold was applied to all images on brown signal to obtain the number of DAB positive pixels and a
second one was applied to the blue signal to obtain number of nuclei pixels. We then used the ratio DAB/hematoxylin to compare
conditions.
T cell transfer
We used 3-5 week old Fosl2tg mice as donors of T cells before the onset of autoimmunity. We used age and sex matched C57Bl6
mice as donors of CD45.2 wt cells, and Ly5.1 mice as donors of CD45.1 wt cells.
Spleens and LN CD4+ T cells were purified by magnetic separation using the CD4 T cell negative isolation kit (Miltenyi Biotec). Pu-
rity was assessed by flow cytometry andwas routinely >95%–98%. Tregs were sorted as CD4+CD25+ to a purity of >98%.More than
95% of these cells were FoxP3+ in subsequent analysis. 6-12 week old sex matched Rag2/ recipients received the indicated cell
numbers by i.v injection in a volume of 200 mL.
Bone marrow transfer
Bone marrow was extracted from the femurs and tibias of 6-8 week old donor mice by flushing the bones with PBS using a 24G nee-
dle. Red blood cells were lysed using RBC lysis buffer (Biolegend). T cells were depleted using biotinylated anti-CD3 antibody
coupled to avidin magnetic beads (Miltenyi Biotec). 6-12 week old Rag2/ sex-matched mice were used as recipients. One
week prior to the experiment, recipient mice were treated with antibiotics in drinking water: Sulfodoxinum (1.33 mg/ml final concen-
tration) and Trimethoprimum (0.26mg/mL final concentration). They then received a 500 rad irradiation split in 2 doses, 4 h apart, 24 h
before transfer of the bonemarrow. Each recipient received 5*106 bonemarrow cells by intravenous injection in the tail in a volume of
200 mL. Antibiotic treatment was continued for one week after bone marrow reconstitution.
Treg suppression assay
For the in vitro Treg suppression assay, we sorted CD4+CD25+CD62LlowCD44high cells as Tregs and CD4+CD25- cell as responders
(Tresp). We used CD4- splenocytes as antigen presenting cells (APC). To avoid proliferation of APCs, we treated them for 3 h with
50 mg/mL mytomycin C (Sigma-Aldrich), in medium at 37C, followed by extensive washing to remove residual mytomycin C.
To follow the proliferation of Tresp, we stained them with Cell Trace Violet (Invitrogen) prior to the assay. In round bottom
96 well plates, we seeded 200 000 APCs with 40 000 Tresps. Cells were stimulated with soluble anti-CD3 at a final concentration
of 1 mg/ml. Tregs were added at the following Tresp/Treg ratios: 1:0, 1:1, 2:1, 4:1 and 8:1. After four days, we used propidium
iodide to exclude dead cells and proliferation of live Tresp was measured by analysis of the number of cell divisions within the
Cell Trace Violet+ Tresp cells.Cell Reports 31, 107826, June 30, 2020 e4
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For in vitro T cell polarization, naive CD4+CD62LhighCD44low cells were sorted. Ninety-six or 24 well plates were coated with anti-CD3
antibodies (2 mg/ml) for 2 h at 37C andwashed. We used anti-CD28 as co-stimulation (2 mg/ml). Polarization was induced as follows:
Th1 mIL-12 (20 ng/ml) anti-IL-4 (1 mg/ml); Th2 mIL-4 (20 ng/ml) anti-IFNg (1 mg/ml); Th17 mIL-6 (60 ng/ml) hTGFb (1 ng/ml) anti-IL-4
(1 mg/ml) anti-IFNg (1 mg/ml); iTreg: hTGFb (10 ng/ml) anti-IL-4 (1 mg/ml) anti-IFNg (1 mg/ml). After three days of stimulation, CD3/CD28
stimulation was stopped and cells were transferred to new wells with the same polarization conditions. Two days later, polarization
was assessed by analysis of cytokine production and expression of FoxP3 as described in the flow cytometry section.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were done usingGraphPad Prism 8.0.0. As sample size in certain experiments was limited to determine normal
distribution and since our size effect and statistical power was not a limitation we used non parametric tests, and plotted the median.
The statistic test used and number of biological replicates is detailed in the legend of each figure. We also used dot plots to display
individual values to better represent data distribution.e5 Cell Reports 31, 107826, June 30, 2020
